Menu Back to DIA-Annual-Canadian-Meeting

Overview

Short Courses: November 4
Meeting: November 5-6

The DIA Annual Canadian Meeting will deliver a comprehensive overview of the current bio-pharma and device landscape in Canada, while sharing insights into Canada’s broader role in global healthcare product development. From policy updates and priorities shared directly from Health Canada, to sessions on international work sharing and partnerships to key regulatory and clinical considerations for drugs and devices, you will have the exclusive opportunity to address the current issues and opportunities in Canada and across the globe.

Bringing together key stakeholders from the drug/device and Patient Self Care industries, regulatory agencies, and academia, this meeting will discuss and analyze the relevant challenges and opportunities for professionals working in the field in Canada.


Need approval in order to attend?

Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.

Check out our 2019 Program!


Preconference Short Course


Why Attend?


Who should attend?

Professionals in pharmaceutical and device industries, regulatory agencies, and academia involved in:

  • Clinical data management/eClinical
  • Comparative effectiveness/health technology assessment
  • Clinical safety/pharmacovigilance
  • Clinical research
  • Document management/eSubmissions
  • Medical communications
  • Outsourcing
  • Project management
  • Public policy/law/corporate compliance
  • Quality assurance control
  • Regulatory affairs
  • Research and development
  • Statistics

Learning objectives

At the end of this session, participants should be able to:
  • Describe the current and evolving regulatory environment in Canada
  • Summarize current methods used in clinical trials, patient engagement, and improving market access
  • Discuss approaches on international harmonization, work sharing, and implementation of current guidelines
  • Review the various levels of transparency needed to maintain compliance in pre- and post-market activities

Program Committee

  • Marc F. Poitras, PhD, MBA
    Marc F. Poitras, PhD, MBA Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
    Health Canada, Canada
  • Lisa  Chartrand
    Lisa Chartrand Director, Regulatory Strategy and Policy
    Hoffmann-La Roche Limited, Canada
  • Loretta  Del Bosco
    Loretta Del Bosco Director, Regulatory Affairs Quality Assurance Operations
    AbbVie Corporation, Canada
  • Fiona  Frappier, PhD
    Fiona Frappier, PhD Senior Policy Analyst
    Health Canada, Canada
  • Lorella  Garofalo, PhD
    Lorella Garofalo, PhD Director, Regulatory Affairs Canada; Global Regulatory Affairs International
    Pfizer Canada ULC, Canada
  • Melissa  Hunt, MSc
    Melissa Hunt, MSc Director
    Health Canada, Canada
  • Yatika  Kohli, PhD, MBA
    Yatika Kohli, PhD, MBA Executive Director - Global Regulatory Affairs
    NoNO Inc, Canada
  • Rania  Mouchantaf, PhD
    Rania Mouchantaf, PhD Associate Director, Bureau of Pharmaceutical Sciences
    Therapeutic Products Directorate, Health Canada, Canada
  • Kristin  Willemsen, MS
    Kristin Willemsen, MS Director of Scientific & Regulatory Affairs
    Consumer Health Products Canada, Canada
Load More